At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
oxytocin 24IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
In Brief
A Phase 2 clinical trial evaluating placebo, oxytocin 24IU, and 1 other intervention for Fragile X Syndrome. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFragile X Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
Primary CompletionNov 2009
Study CompletionJan 2010
First PostedDec 2010
TodayJul 2026
First PostedDec 6, 2010
Enrollment StartFeb 1, 2007
Primary CompletionNov 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.6 years ago
Interventions
placebodrug
intranasal placebo (48 international units)
oxytocin 24IUdrug
intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
oxytocin 48IUdrug
intranasal oxytocin (48 international units)